Use of measles and rubella rapid diagnostic tests to improve case detection and targeting of vaccinations

Centers for Disease Control and Prevention. Global Immunization Division. Atlanta, GA, USA.
Centers for Disease Control and Prevention. Global Immunization Division. Atlanta, GA, USA.
Centers for Disease Control and Prevention. Division of Viral Diseases. Atlanta, GA, USA.
World Health Organization. Department of Immunization, Vaccines and Biologicals. Geneva, Switzerland.
Centers for Disease Control and Prevention. Global Immunization Division. Atlanta, GA, USA.
Centers for Disease Control and Prevention. Global Immunization Division. Atlanta, GA, USA.
Bill & Melinda Gates Foundation. Seattle, WA, USA.
Sound Global Health Consulting. Seattle, WA, USA.
Foundation for Innovative New Diagnostics. Geneva, Switzerland.
Foundation for Innovative New Diagnostics. Geneva, Switzerland.
Global Health Campus. Gavi, the Vaccine Alliance. Geneva, Switzerland / University of Geneva. Faculty of Medicine. Institute of Global Health. Geneva, Switzerland.
Global Health Campus. Gavi, the Vaccine Alliance. Geneva, Switzerland.
UK Health Security Agency. Public Health Microbiology Division. London, UK.
Consultant Scientists Ltd. Hastings, New Zealand.
UK Health Security Agency. Public Health Microbiology Division. London, UK / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Vírus Respiratórios, Exantemáticos, Enterovírus e Emergências Virais. Rio de Janeiro, RJ, Brasil.

Abstract

Efforts to control and eliminate measles and rubella are aided by high-quality surveillance data—supported by laboratory confirmation—to guide decision-making on routine immunization strategies and locations for conducting preventive supplementary immunization activities (SIAs) and outbreak response. Important developments in rapid diagnostic tests (RDTs) for measles and rubella present new opportunities for the global measles and rubella surveillance program to greatly improve the ability to rapidly detect and respond to outbreaks. Here, we review the status of RDTs for measles and rubella Immunoglobulin M (IgM) testing, as well as ongoing questions and challenges regarding the operational use and deployment of RDTs as part of global measles and rubella surveillance. Efforts to develop IgM RDTs that can be produced at scale are underway. Once validated RDTs are available, clear information on the benefits, challenges, and costs of their implementation will be critical for shaping deployment guidance and informing country plans for sustainably deploying such tests. The wide availability of RDTs could provide new programmatic options for measles and rubella elimination efforts, potentially enabling improvements and flexibility for testing, surveillance, and vaccination.

Keywords

Vaccine-preventable disease surveillance
Disease elimination
Diagnostics
Immunization
GMRLN
RDTs

Publisher

MDPI

Citation

RACHLIN, Audrey et al. Use of measles and rubella rapid diagnostic tests to improve case detection and targeting of vaccinations. Vaccines, v. 12, n. 8, p. 1-13, 23 July 2024.

DOI

10.3390/vaccines12080823

ISSN

2076-393X

Notes

Produção científica do Laboratório de Vírus Respiratórios, Exantemáticos, Enterovírus e Emergências Virais.

Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/66319

Type

Copyright

Open access

Sustainable Development Goals

Collections

Share

Statistics

Metadata

Author

Affilliation